Literature DB >> 15509741

Dopamine modulates release from corticostriatal terminals.

Nigel S Bamford1, Siobhan Robinson, Richard D Palmiter, John A Joyce, Cynthia Moore, Charles K Meshul.   

Abstract

Normal striatal function is dependent on the availability of synaptic dopamine to modulate neurotransmission. Within the striatum, excitatory inputs from cortical glutamatergic neurons and modulatory inputs from midbrain dopamine neurons converge onto dendritic spines of medium spiny neurons. In addition to dopamine receptors on medium spiny neurons, D2 receptors are also present on corticostriatal terminals, where they act to dampen striatal excitation. To determine the effect of dopamine depletion on corticostriatal activity, we used the styryl dye FM1-43 in combination with multiphoton confocal microscopy in slice preparations from dopamine-deficient (DD) and reserpine-treated mice. The activity-dependent release of FM1-43 out of corticostriatal terminals allows a measure of kinetics quantified by the halftime decay of fluorescence intensity. In DD, reserpine-treated, and control mice, exposure to the D2-like receptor agonist quinpirole revealed modulation of corticostriatal kinetics with depression of FM1-43 destaining. In DD and reserpine-treated mice, quinpirole decreased destaining to a greater extent, and at a lower dose, consistent with hypersensitive corticostriatal D2 receptors. Compared with controls, slices from DD mice did not react to amphetamine or to cocaine with dopamine-releasing striatal stimulation unless the animals were pretreated with l-3,4-dihydroxyphenylalanine (l-dopa). Electron microscopy and immunogold labeling for glutamate terminals within the striatum demonstrated that the observed differences in kinetics of corticostriatal terminals in DD mice were not attributable to aberrant cytoarchitecture or glutamate density. Microdialysis revealed that basal extracellular striatal glutamate was normal in DD mice. These data indicate that dopamine deficiency results in morphologically normal corticostriatal terminals with hypersensitive D2 receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509741      PMCID: PMC6730145          DOI: 10.1523/JNEUROSCI.2891-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  84 in total

1.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

Authors:  Bonnie G Garcia; M Diana Neely; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2010-01-29       Impact factor: 5.357

2.  Endocannabinoids mediate bidirectional striatal spike-timing-dependent plasticity.

Authors:  Yihui Cui; Vincent Paillé; Hao Xu; Stéphane Genet; Bruno Delord; Elodie Fino; Hugues Berry; Laurent Venance
Journal:  J Physiol       Date:  2015-05-13       Impact factor: 5.182

3.  Differential synaptology of vGluT2-containing thalamostriatal afferents between the patch and matrix compartments in rats.

Authors:  Dinesh V Raju; Deep J Shah; Terrence M Wright; Randy A Hall; Yoland Smith
Journal:  J Comp Neurol       Date:  2006-11-10       Impact factor: 3.215

4.  Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys.

Authors:  Rosa M Villalba; Yoland Smith
Journal:  J Comp Neurol       Date:  2011-04-01       Impact factor: 3.215

5.  L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study.

Authors:  Clare Kelly; Greig de Zubicaray; Adriana Di Martino; David A Copland; Philip T Reiss; Donald F Klein; F Xavier Castellanos; Michael P Milham; Katie McMahon
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

6.  Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration.

Authors:  Nigel S Bamford; Hui Zhang; John A Joyce; Christine A Scarlis; Whitney Hanan; Nan-Ping Wu; Véronique M André; Rachel Cohen; Carlos Cepeda; Michael S Levine; Erin Harleton; David Sulzer
Journal:  Neuron       Date:  2008-04-10       Impact factor: 17.173

Review 7.  Looking for the role of cannabinoid receptor heteromers in striatal function.

Authors:  Sergi Ferré; Steven R Goldberg; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

8.  Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency.

Authors:  Z Zhang; J E Quintero; X T Fan; F Zhao; Y Ai; A Andersen; P Hardy; F Ling; G A Gerhardt
Journal:  Brain Res       Date:  2014-01-04       Impact factor: 3.252

Review 9.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

10.  Overinhibition of corticostriatal activity following prenatal cocaine exposure.

Authors:  Wengang Wang; Ioana Nitulescu; Justin S Lewis; Julia C Lemos; Ian J Bamford; Natasza M Posielski; Granville P Storey; Paul E M Phillips; Nigel S Bamford
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.